Biotherapeutics developer Avacta Group released its unaudited interim results for the period ended 31 January on Monday, reporting half-year revenues of £1.5m - up 16% year-on-year - comprising £0.7m from Avacta Life Sciences and £0.8m from Avacta Animal Health. The AIM-traded firm reported an operating loss of £4.5m, widening from £3.9m year-on-year, with research and development costs increasing to £1.5m from £1.3m. Its reported loss totalled £3.9m, widening from £3.4m. Cash balances ...Den vollständigen Artikel lesen ...